History of U.S. military contributions to the study of diarrheal diseases

Military Medicine

Volumn 170, Issue 4 SUPPL., 2005, Pages 30-38

  Lim, Matthew L ^a   Murphy, Gerald S ^a   Calloway, Margaret ^b   Tribble, David ^c  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b Military Tropical Medicine Course   (United States)

^c NAVAL MEDICAL RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZITHROMYCIN; BACTERIAL VACCINE; CAMPYLOBACTER VACCINE; CEPHALOSPORIN; CHLORAMPHENICOL; CHOLERA TOXIN; CHOLERA VACCINE; CIPROFLOXACIN; DEXAMETHASONE; LOPERAMIDE; MACROLIDE; ORAL REHYDRATION SOLUTION; QUINOLONE DERIVATIVE; TYPHOID VACCINE; UNCLASSIFIED DRUG;

CAMPYLOBACTER JEJUNI; CAMPYLOBACTERIOSIS; CHLORINATION; CHOLERA; CLINICAL TRIAL; CONFERENCE PAPER; DESQUAMATION; DIARRHEA; DRUG USE; DYSENTERY; ELECTROLYTE BALANCE; FLUID BALANCE; GRAM NEGATIVE INFECTION; HUMAN; HYDRATION; INOCULATION; MILITARY MEDICINE; MORTALITY; NONHUMAN; ORAL REHYDRATION THERAPY; PATHOGENESIS; TRAVELLER DIARRHEA; TYPHOID FEVER; UNITED STATES;

EID: 17444419009     PISSN: 00264075     EISSN: None     Source Type: Journal    
DOI: 10.7205/milmed.170.4s.30     Document Type: Conference Paper

References (75)

1. Bayne-Jones S: The Evolution of Preventive Medicine in the United States Army, 1607-1939, p 45. Washington, DC, Office of the Surgeon General, Department of the Army, 1968.
2. Bayne-Jones S: The Evolution of Preventive Medicine in the United States Army, 1607-1939, p 86. Washington, DC, Office of the Surgeon General, Department of the Army. 1968.
3. Heaton LD, Blumberg JM: Lt Col. Joseph J. Woodward (1833-1884): U.S. Army pathologist-researcher-photomicroscopist. Milit Med 1966; 131: 530-8.
4. Bayne-Jones S: The Evolution of Preventive Medicine in the United States Army, 1607-1939, p 113. Washington, DC, Office of the Surgeon General, Department of the Army, 1968.
5. van Heyningen WE, Seal JR: Cholera: The American Scientific Experience, 1947-1980. Boulder, CO, Westview Press, 1983.
6. Phillips RA: Cholera in the perspective of 1966. Ann Intern Med 1966; 65: 922-30.
7. Phillips RA, Van Slyke DD, Hamilton PB, Dole VP, Emerson K, Archibald RM: Measurement of specific gravity of whole blood and plasma by standard copper sulfate solutions. J Biol Chem 1950; 183: 305.
8. Watten RH, Morgan FM, Songkhla YN, Vanikiati B, Phillips RA: Water and electrolyte studies in cholera. J Clin Invest 1959; 38: 1879-89.
9. Crosby WH, Kugler HW: Intraluminal biopsy of the small intestine: the intestinal biopsy capsule. Am J Digest Dis 1957; 2: 236-41.
10. Gangarosa EF, Beisel WR, Benyayati C, Sprinz H, Piyaratn P: The nature of the gastrointestinal lesion in Asiatic cholera and its relation to pathogenesis: a biopsy study. Am J Trop Med Hyg 1960; 9: 125-35.
11. Gordon RS: The failure of Asiatic cholera to give rise to "exudative enteropathy." Presented at the SEATO Conference on Cholera, December 5-8, 1960, Dacca, East Pakistan.
12. Taylor JO, Sachar DB, Kinzie JL, Phillips RA: Enhancement of net sodium and water absorption in acute human cholera by intestinal glucose lavage. Presented at the Symposium on Cholera, July 26-28, 1967, Palo Alto, CA.
13. Sachar DB, Taylor JO, Kinzie JL, Sana JR: Transmural electric potentiates and their response to sugars in the intestine of acute cholera patients and normal subjects. Presented at the Symposium on Cholera, July 26-28, 1967, Palo Alto, CA.
14. Hirschhorn N, Kinzie JL, Sachar DB, et al: Decrease in net stool output in cholera during intestinal perfusion with glucose-containing solutions. N Engl J Med 1968; 279: 176-81.
15. Carpenter CC: The treatment of cholera: clinical science at the bedside. J Infect Dis 1992; 166: 2-14.
16. Anonymous: Water with sugar and salt [editorial]. Lancet 1978; 2: 300-1.
17. Finkelstein RA, Norris HT, Dutta NK: Pathogenesis of experimental cholera in infant rabbits. 1. Observations on the intraintestinal infective and experimental cholera produced with cell-free products. J Infect Dis 1964; 1124: 203-16.
18. Benyajati C: Experimental cholera in humans. Br Med J 1966; 1: 140-2.
19. Finkelstein RA, LoSpalluto JJ: Pathogenesis of experimental cholera: preparation and isolation of choleragen and choleragenoid. J Exp Med 1969; 130: 185-202.
20. Sanchez JL, Trofa AF, Taylor DN, et al: Safety and immunogenicity of the oral, whole cell/recombinant B subunit cholera vaccine in North American volunteers. J Infect Dis 1993; 167: 1446-9.
21. Sanchez JL, Vasquez B, Begue RE, et al: Protective efficacy of oral whole-cell/ recombinant-B-subunit cholera vaccine in Peruvian military recruits. Lancet 1994; 344: 1273-6.
22. Taylor DN, Cardenas V, Sanchez JL, et al: Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru. J Infect Dis 2001; 183: 1306-9.
23. Taylor DL, Killeen KP, Hack DC, et al: Development of a live, oral, attenuated vaccine against El Tor cholera. J Infect Dis 1994; 170: 1518-23.
24. Coster TS, Killeen KP, Waldor MK, et al: Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet 1995; 345: 949-52.
25. Su-Arehawaratana P, Singharaj P, Taylor DN, et al: Safety and immunogenicity of different immunization regimens of CVD 103-HgR live oral cholera vaccine in soldiers and civilians in Thailand. J Infect Dis 1992; 165: 1042-8.
26. Richie EE, Punjabi NH, Sidharta YY, et al: Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 2000; 18: 2399-410.
27. Lim ML, Wallace MR: Infectious diarrhea in history. Infect Dis Clin N Am 2004; 18: 261-74.
28. Gianella RA: Enteric infections: 50 years of progress. Gastroenterology 1993; 104: 1589-94.
29. DuPont HL, Levine MM, Hornick RB, Formal SB: Inoculum size in shigellosis and implications for expected mode of transmission. J Infect Dis 1989; 159: 1126-8.
30. O'Brien AD, LaVeck GD, Thompson MR, Formal SB: Production of Shigella dysenteriae type 1-like cytotoxin by Escherichia coli. J Infect Dis 1982; 146: 763-9.
31. O'Brien AO, Lively TA, Chen ME, Rothman SW, Formal SB: Escherichia coli O157:H7 strains associated with haemorrhagic colitis in the United States produce a Shigella dysenteriae 1 (Shiga)-like cytotoxin. Lancet 1983; 1: 702.
32. Murphy GS, Bodhidatta L, Echeverria P, et al: Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann Intern Med 1993; 118: 582-6.
33. Oldfield EC, Bourgeois AL, Omar AK, Pazzaglia GL: Empirical treatment of Shigella dysentery with trimethoprim: five-day course vs. single dose. Am J Trop Med Hyg 1987; 37: 616-23.
34. Formal SB, Hale TL, Kapfer C: Shigella vaccines. Rev Infect Dis 1989; 11(Suppl 3): S547-51.
35. Katz DE, Coster TS, Wolf MK, et al: Two studies evaluating the safety and immunogenicity of a live, attenuated Shigella flexneri 2a vaccine (SC602) and excretion of vaccine organisms in North American volunteers. Infect Immunol 2004; 72: 923-30.
36. Hyams KC, Bourgeois AL, Merrell BR, et al: Diarrheal disease during Operation Desert Shield. N Engl J Med 1991; 325: 1423-8.
37. Allos BM: Campylobacter jejuni infections: update on emerging issues and trends. Clin Infect Dis 2001; 32: 1201-6.
38. Guerry P, Alm R, Szymanksi C, Trust TJ: Structure, function, and antigenicity of Campylobacter flagella. In: Campylobacter, Ed 2, pp 405-21. Edited by Nachamkin I, Blaser MJ. Washington, DC, ASM Press, 2000.
39. Scott DA: Vaccines against Campylobacter jejuni. J Infect Dis 1997; 176(Suppl 2): S183-8.
40. Lee LH, Burg E, Baqar S, et al: Evaluation of a truncated recombinant flagellin subunit vaccine against Campylobacter jejuni. Infect Immunol 1999; 67: 5799-805.
41. Baqar S, Bourgeois AL, Schultheiss PJ, et al: Safety and immunogenicity of a prototype oral whole-cell killed Campylobocter vaccine administered with a mucosal adjuvant in non-human primates. Vaccine 1995; 13: 22-8.
42. Hoge CW, Gambel JM, Srijan A, Pitarangsi C, Echeverria P: Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26: 341-5.
43. Kuschner RA, Trofa AF, Thomas FJ, et al: Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resistance is prevalent. Clin Infect Dis 1995; 21: 536-41.
44. Bayne-Jones S: The Evolution of Preventive Medicine in the United States Army, 1607-1939, pp 123-46. Washington, DC, Office of the Surgeon General, Department of the Army, 1968.
45. Siler JF, Lambie JS: Typhoid and the paratyphoid fevers. in: The Medical Department of the United States Army in the World War, Vol IX, pp 15-60. Edited by Lynch C, Weed FW, McAfee L. Washington, DC, Office of the Surgeon General, Department of the Army, 1928.
46. Woodward TE, Smadel JE, Ley HL, Green R, Mankikan DS: Preliminary report on beneficial effect of chloromycetin in treatment of typhoid fever. Ann Intern Med 1948; 29: 131-4.
47. Hoffman SL, Punjabi NH, Kumala S, et al: Reduction of mortality in chloramphenicol-treated severe typhoid fever by high-dose dexamethasone. N Engl J Med 1984; 310: 82-8.
48. Tribble D, Girgis N, Habib N, Butler T: Efficacy of azithromycin for typhoid fever. Clin Infect Dis 1995; 21: 1045-6.
49. Frenck RW, Nakhla I, Sultan Y, et al: Azithromycin versus ceftriaxone for the treatment of uncomplicated typhoid fever in children. Clin Infect Dis 2000; 31: 1134-8.
50. Girgis NI, Butler T, Frenck RW, et al: Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob Agents Chemother 1999; 43: 1441-4.
51. Wallace MR, Yousif AA, Mahroos GA, et al: Ciprofloxacin versus ceftriaxone in the treatment of multiresistant typhoid fever. Eur J Clin Microbiol Infect Dis 1993; 12: 907-10.
52. Gaines S, Landy M, Edsall G, Mandel AD, Trapani FJ, Benenson AS: Studies on infection and immunity in experimental typhoid fever. III. Effect of prophylactic immunization. J Exp Med 1961; 114: 327-42.
53. Wahdan MH, Serie C, Germanier R, et al: A controlled field trial of liver oral typhoid vaccine Ty21a. Bull World Health Organ 1980; 58: 469-74.
54. Kean BH: The diarrhea of travelers to Mexico: summary of five-year study. Ann Intern Med 1963; 59: 605-14.
55. Hyams KC, Bourgeois AL, Merrell BR, et al: Diarrheal disease during Operation Desert Shield. N Engl J Med 1991; 325: 1423-8.
56. Hoge CW, Gambel JM, Srijan A, Pitarangsi C, Echeverria P: Trends in antibiotic resistance among diarrheal pathogens isolated in Thailand over 15 years. Clin Infect Dis 1998; 26: 341-5.
57. Taylor DN, Echeverria P: Etiology and epidemiology of travelers' diarrhea in Asia. Rev Infect Dis 1986; 8(Suppl 2): S136-41.
58. Bayne-Jones S: The Evolution of Preventive Medicine in the United States Army, 1607-1939, pp 57-59. Washington, DC, Office of the Surgeon General, Department of the Army, 1968.
59. Hume EE: Victories of Army Medicine: Scientific Accomplishments of the Medical Department of the United States Army. Philadelphia, PA, J.P. Lippincott, 1943.
60. Darnall CR: The purification of water by anhydrous chlorine. J Am Public Health Assoc 1911; 1: 783-97.
61. Lyster WJ: Sterilization of drinking water by calcium hypochlorite in the field. Milit Surg 1915; 36: 222-8.
62. Wood MJ, Hornick RB: Commission on enteric infections. In: The Armed Forces Epidemiological Board: Histories of the Commissions, pp 385-436. Edited by Woodward TE. Washington, DC, Borden Institute, Office of the Surgeon General, Department of the Army, 1994.
63. DuPont HL, Formal SB, Hornick RB, et al: Pathogenesis of Escherichia coli diarrhea. N Engl J Med 1971; 285: 1-9.
64. Wolf MK, Taylor DN, Boedeker EC, et al: Characterization of enterotoxigemc Escherichia coli isolated from U.S. troops deployed to the Middle East. J Clin Microbiol 1993; 31: 851-6.
65. Wolf MK: Occurrence, distribution, and associations of O and H serogroups, colonization factor antigens, and toxins of enterotoxigenic Escherichia coli. Clin Microbiol Rev 1997; 10: 569-84.
66. Petruccelli BP, Murphy GS, Sanchez JL, et al: Treatment of traveler's diarrhea with ciprofloxacin and loperamide. J Infect Dis 1992; 165: 557-60.
67. Echeverria P, Sack RB, Blacklow NR, Bodhidatta P, Rowe B, McFarland A: Prophylactic doxycycline for travelers' diarrhea in Thailand: further supportive evidence of Aeromonas hydrophila as an enteric pathogen. Am J Epidemiol 1984; 120: 912-21.
68. Scott DA, Haberberger RL, Thornton SA, Hyams KC: Norfloxacin for the prophylaxis of travelers' diarrhea in U.S. military personnel. Am J Trop Med Hyg 1990; 42: 160-4.
69. Savarino SJ, Brown FM, Hall E, et al: Safety and immunogenicity of an oral, killed enterotoxigenic Escherichia coli-cholera toxin B subunit vaccine in Egyptian adults. J Infect Dis 1998; 177: 796-9.
70. Savarino SJ, Hall ER, Bassily S, et al: Oral, inactivated, whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine: results of the initial evaluation in children: PRIDE Study Group. J Infect Dis 1999; 179: 107-14.
71. Wolf MK, de Haan LA, Cassels FJ, et al: The CS6 colonization factor of human enterotoxigenic Escherichia coli contains two heterologous major subunits. FEMS Microbiol Lett 1997; 148: 35-42.
72. Guerena-Burgueno F, Hall ER, Taylor DN, et al: Safety and immunogenicity of a prototype enterotoxigenic Escherichia coli vaccine administered transcutaneously. Infect Immunol 2002; 70: 1874-80.
73. Scerpella EG, Sanchez JL, Mathewson JJ, et al: Safety, immunogenicity, and protective efficacy of the whole-cell/recombinant B subunit (WC/rBS) oral cholera vaccine against travelers' diarrhea. J Travel Med 1995; 2: 22-7.
74. Hall ER, Wierzba TF, Ahren C, et al: Induction of systemic antifimbria and antitoxin antibody responses in Egyptian children and adults by an oral, killed enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine. Infect Immunol 2001; 69: 2853-7.
75. Savarino SJ, Hall ER, Bassily S, et al: Introductory evaluation of an oral, killed whole cell enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Egyptian infants. Pediatr Infect Dis J 2002; 21: 322-30.